Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300?U/mL versus insulin glargine 100?U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use.

ABSTRACT: AIM:To explore if clinical effects and hypoglycaemia risks associated with insulin glargine 300?U/mL (Gla-300) and 100?U/mL (Gla-100) differed by sulphonylurea and/or glinide (SU/G) treatment. METHODS:A post hoc subgroup analysis of 12-month treatment data from the EDITION Japan 2 trial, a randomized, open-label, phase 3 study of Japanese people with type 2 diabetes receiving once-daily Gla-300/Gla-100?+?oral antihyperglycaemic drugs. Participants previously receiving SU/G (+SU/G) were compared with those not taking SU/G (-SU/G). Endpoints included HbA1c, hypoglycaemia and body weight. RESULTS:For +SU/G (n?=?152, 63%), HbA1c was reduced from baseline to month 12 for Gla-300 (8.1% to 7.6%) and Gla-100 (8.2% to 7.8%). For -SU/G (n?=?89, 37%), reductions were 7.8% to 7.4%, and 7.9% to 7.5% for Gla-300 and Gla-100, respectively. A lower annualized rate of hypoglycaemia with Gla-300 versus Gla-100 was observed at night (00:00-05:59?hours; p?=?0.0001) and any time of day (24?hour; p?=?0.0015). Irrespective of the insulin used, the incidence and rate of confirmed (?3.9 mmol/L [?70?mg/dL]) or severe hypoglycaemia appeared higher in +SU/G versus -SU/G; overall, a reduced incidence of nocturnal hypoglycaemia, and rate of hypoglycaemia at any time, was observed in -SU/G versus +SU/G. In the -SU/G subgroup, body weight gain differences were observed between Gla-300 and Gla-100 (p?

SUBMITTER: Terauchi Y 

PROVIDER: S-EPMC6585671 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature